The effect of the tumour necrosis factor-alpha-inhibitor etanercept on microglial activation patients with mild cognitive impairment—a PET study

Abstract

Aim: Microglial activation is increasingly recognised as a factor in the progression of Alzheimer’s disease (AD) and may be modified by systemic inflammatory signals including serum tumour necrosis factor (TNF)-α. The aim was to investigate whether blockade of peripheral TNF-α with peripheral inhibitors such as etanercept reduces microglial activation in prodromal AD.Methods: A one-year, multi-centre, phase 2, double-blind randomised placebo-controlled trial (RPCT) was performed, to assess the effect of weekly 50 mg s.c. etanercept in amyloid positive mild cognitive impaired participants on the change in microglial activation as measured by [11C](R)-PK11195 positron emission tomography (PET). Secondary objectives were to ascertain the change in cortical amyloid load on PET and the change in the Montreal Cognitive Assessment (MoCA).Results: Forty-four subjects consented to the study. Twenty-eight subjects failed screening including six subjects who were amyloid negative on visual read of the Amyvid^TM PET scans. Thirteen of sixteen subjects with mild cognitive impairment (MCI) due to AD completed the baseline [11C](R)-PK11195 PET scan and were randomised to either placebo or etanercept. Three patients who consented were not able to complete screening due to early termination of the study following delays in study commencement. [11C](R)-PK11195 binding potential (BP) at baseline showed an almost global increase in MCI patients as compared to age-matched controls. Compliance to medication was high over the twelve-month trial period with etanercept being well tolerated. The study did not achieve statistical power to show a significant effect of etanercept over 52 weeks in the limited number of patients with MCI on microglial activation as measured by [11C](R)-PK11195 PET. Overall uptake of florbetapir in the follow up (FU) scans remained stable. The study was not powered to show statistical differences in psychometric ratings between groups.Conclusions: This study did not show evidence that treatment with etanercept over one year would modulate microglial activation in amyloid positive MCI patients (EudraCT identifier: 2015-002145-63, https://www.clinicaltrialsregister.eu; International Standard Randomised Controlled Trial Number identifier: ISRCTN12472821, https://www.isrctn.com).

Keywords

Alzheimer’s disease / mild cognitive impairment / positron emission tomography / inflammation / randomised placebo-controlled trial

References

[1] Webers AHeneka MTGleeson PA. The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer’s disease. Immunol Cell Biol. 2020;98:28–41..

[2] Ginhoux FLim SHoeffel GLow DHuber T. Origin and differentiation of microglia. Front Cell Neurosci. 2013;7:45.

[3] Song WMColonna M. The identity and function of microglia in neurodegeneration. Nat Immunol. 2018;19:1048–58..

[4] Taipa RBrochado PRobinson AReis ICosta PMann DMet al. Patterns of microglial cell activation in Alzheimer disease and frontotemporal Lobar Degeneration. Neurodegener Dis. 2017;17:145–54..

[5] Papadopoulos VBaraldi MGuilarte TRKnudsen TBLacapère JJLindemann Pet al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27:402–9..

[6] Turkheimer FERizzo GBloomfield PSHowes OZanotti-Fregonara PBertoldo Aet al. The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans. 2015;43:586–92..

[7] Perani DIaccarino LJacobs AHIMBI Brain Imaging Working Group. Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. Alzheimers Dement (Amst). 2019;11:327–32..

[8] Boche DGerhard ARodriguez-Vieitez EMINC Faculty. Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2019;46:2831–47..

[9] Okello AEdison PArcher HATurkheimer FEKennedy JBullock Ret al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009;72:56–62..

[10] Parbo PIsmail RHansen KVAmidi AMårup FHGottrup Het al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease. Brain. 2017;140:2002–11..

[11] Drake CBoutin HJones MSDenes AMcColl BWSelvarajah JRet al. Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun. 2011;25:1113–22..

[12] Holmes CCunningham CZotova EWoolford JDean CKerr Set al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73:768–74..

[13] Butchart JBrook LHopkins VTeeling JPüntener UCulliford Det al. Etanercept in Alzheimer disease: a randomised, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015;84:2161–8..

[14] Albert MSDeKosky STDickson DDubois BFeldman HHFox NCet al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9..

[15] Hachinski VCIliff LDZilhka EDu Boulay GHMcAllister VLMarshall Jet al. Cerebral blood flow in dementia. Arch Neurol. 1975;32:632–7..

[16] Kobylecki CLangheinrich THinz RVardy ERLCBrown GMartino MEet al. ¹⁸F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease. J Nucl Med. 2015;56:386–91..

[17] Joshi ADPontecorvo MJClark CMCarpenter APJennings DLSadowsky CHet al.Florbetapir F 18 Study Investigators. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects. J Nucl Med. 2012;53:378–84..

[18] Hammers AKoepp MJRichardson MPHurlemann RBrooks DJDuncan JS. Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients. Brain. 2003;126:1300–18..

[19] Su ZHerholz KGerhard ARoncaroli FDu Plessis DJackson Aet al. [¹¹C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. Eur J Nucl Med Mol Imaging. 2013;40:1406–19..

[20] Robb RAHanson DP. A software system for interactive and quantitative visualization of multidimensional biomedical images. Australas Phys Eng Sci Med. 1991;14:9–30..

[21] Nasreddine ZSPhillips NABédirian VCharbonneau SWhitehead VCollin Iet al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9..

[22] Grober EBuschke HCrystal HBang SDresner R. Screening for dementia by memory testing. Neurology. 1988;38:900.

[23] Randolph CTierney MCMohr EChase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310–9..

[24] Dodel RSpottke AGerhard AReuss AReinecker SSchimke Net al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [¹¹C] (R)-PK11195 PET (MEMSA-trial). Mov Disord. 2010;25:97–107..

[25] Kübler DWächter TCabanel NSu ZTurkheimer FEDodel Ret al. Widespread microglial activation in multiple system atrophy. Mov Disord. 2019;34:564–8..

[26] Turkheimer FEEdison PPavese NRoncaroli FAnderson ANHammers Aet al. Reference and target region modeling of [¹¹C]-(R)-PK11195 brain studies. J Nucl Med. 2007;48:158–67..

[27] Hamelin LLagarde JDorothée GPotier MCCorlier FKuhnast Bet al. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer’s disease. Brain. 2018;141:1855–70..